Estimated baseline disease characteristics of subjects in the CHABLIS-SC1 study and in Phase 3 trials with other BAFF inhibitors
| Blisibimod | Belimumab | Tabalumab | |
|---|---|---|---|
| (CHABLIS-SC1) | (BLISS Trials) | (ILLUMINATE Trials) | |
| Total randomized (N) | 442 | 1664 | 2288 |
| Mean age (years) | 36.3 | 35.3 | 40.7 |
| Female (%) | 93.9 | 94.1 | 91.9 |
| Mean SELENA- SLEDAI | 13.6 | 9.7 | 10.3 |
| Receiving corticosteroids (%) | 100 | 86.3 | 75.3 |
| ANA ≥1:80 (%) | 98.9 | 93.0 | – |
| +Anti-dsDNA (%) | 85.5 | 69.4 | 59.2 |
| Low C3 <90mg/dL (%) | 53.9 | 45.0 | 39.4 |
| Low C4 <16mg/dL (%) | 48.2 | 56.1 | 22.5 |
| +Anti-dsDNA & Low C3/C4 (%) | 59.7 | 52.6 | 35.0 |
| Protein:Creatinine ≥1g/g (%) | 19.7 | 13.1 | [Pr:Cr ≥0.4 10.4%] |
| Protein:Creatinine >2g/g (%) | 9.5 | 5.9 | – |